SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

NCT ID: NCT06122389

Last Updated: 2026-01-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 130 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-05
• Study Completion Date: 2026-07-31

Brief Summary

This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.

Conditions

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment group A

Group Type: EXPERIMENTAL

SHR2554; Chidamide analog tablets

Intervention Type: DRUG

SHR2554 + Chidamide analog tablets

Treatment group B

Group Type: EXPERIMENTAL

SHR2554 analog tablets; Chidamide

Intervention Type: DRUG

SHR2554 analog tablets + Chidamide

Interventions

SHR2554; Chidamide analog tablets

SHR2554 + Chidamide analog tablets

Intervention Type: DRUG

SHR2554 analog tablets; Chidamide

SHR2554 analog tablets + Chidamide

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 18-70 years old (including 18 and 70 years old), gender is not limited;

2. Histologically confirmed T-cell lymphoma;

3. ECOG physical status must be 0 or 1;

4. Life expectancy ≥12 weeks;

5. For relapsed refractory patients who have received ≥ first-line treatment, at least one prior treatment is adequate;

6. Have not received histone deacetylase inhibitors;

7. Have measurable lesions;

8. Bone marrow function is basically normal;

9. Liver and kidney function is basically normal;

10. Blood coagulation function is basically normal;

11. Female subjects with a possibility of becoming pregnant must undergo a blood pregnancy test prior to the first dose, with a negative result, and be willing to use a highly effective method of contraception for 90 days after signing the notification until the last dose of the study drug. Male subjects whose partners are women at risk of becoming pregnant should be surgically sterilized or agree to use highly effective methods of contraception for 90 days from the date of signing the notification until the last administration of the study drug;

12. The subject has recovered from the toxic effects of the last treatment before the first dosing;

13. The subject personally signs and dates the informed consent to show that the subject has been fully informed of all the circumstances related to the clinical trial;

14. Subjects are willing and able to comply with visit schedules, dosing schedules, laboratory examinations, and other clinical trial procedures.

Exclusion Criteria

1. Have been treated with compounds with the same mechanism;

2. Accompanied by central nervous system infiltration;

3. Received autologous stem cell transplantation within 60 days before signing the agreement, and received allogeneic stem cell transplantation within 90 days;

4. Major surgery or severe trauma occurred 4 weeks before the first dose of study drug administration;

5. Received anti-tumor treatment within 4 weeks before the first dose of the study drug, and received Chinese medicine treatment with anti-tumor effect within 2 weeks before the first dose of the study drug; Receiving steroid hormones within 7 days prior to the first dose of study drug administration;

6. Active phase of HBV or HCV infection;

7. A history of immunodeficiency, including HIV seropositive, or other acquired or congenital immunodeficiency diseases;

8. Active infection or unexplained fever > 38.5°C within 2 weeks of initial dosing;

9. A history of clinically severe cardiovascular disease;

10. Abnormal electrocardiogram (ECG) examination;

11. Cerebrovascular accident or transient ischemic attack occurred within 6 months before entering the study;

12. Have other malignancies within 5 years prior to screening, other than adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery (allowing hormone therapy for non-metastatic prostate cancer or breast cancer), and papillary thyroid cancer;

13. The subject has another serious/severe acute or chronic illness or mental illness, including recent (within the past year) or current suicidal ideation or behavior, or laboratory abnormalities that may increase the risks associated with participation in the study or administration of the investigational drug, may interfere with the interpretation of the study results, or may interfere with the investigator's judgment;

14. The subjects are the staff of the research center directly related to this clinical trial or their family members, or the subordinates of this trial although not directly related to this trial, or the staff employed by the sponsor directly related to this trial;

15. Pregnant and lactating women;

16. The subject is unable to swallow, or has a history of active gastrointestinal inflammation, chronic diarrhea, known diverticulosis, or a history of gastrectomy or gastric banding that affects drug absorption;

17. The subject is taking a known medium or strong CYP inducer;

18. In the judgment of the investigator, objective conditions (including the subject's psychological state, family relationship, social factors or geographical factors) make the subject unable to complete the planned study or the subject has other factors, concomitant diseases, combined treatment or abnormal laboratory examination that may lead to the forced termination of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Peking University Cancer Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Min Li

Role: CONTACT

Min.li.ml150@hengrui.com

0518-82342973

Facility Contacts

Yuqin Song, Doctor

Role: primary

songYQ_vip@163.com

010-88196118

Other Identifiers

SHR2554-301

Identifier Type: -

Identifier Source: org_study_id